Feb. 24, 2012 13:00 UTC
LEXINGTON, Mass.--(BUSINESS WIRE)--
RainDance Technologies, Inc., the Digital Biology? company, today
announced that President and CEO Roopom Banerjee will provide a company
overview, discuss strategic initiatives, and highlight new product
launches at the Citi Global Health Care Conference in New York on
Monday, February 27 at 1:30pm ET.
RainDance continues to power ground-breaking human genetics and cancer
research with its novel picodroplet-based technologies. The company
offers a full portfolio of integrated cancer analysis solutions,
including fully automated instrumentation, a sophisticated primer design
pipeline, and high-value consumables and reagents for applications such
as
Targeted DNA Sequencing, ultra-deep sequencing of FFPE samples (DeepSeq?
FFPE Solution), cancer hotspot mutation detection, cancer pathway
analysis (ONCOSeq?
Panel), methylation analysis (MethylSeq?
Solution), Digital
PCR, and in the future, single cell analysis.
"The application of genomic information to life science research and
clinically focused applications are areas of tremendous growth and
opportunity for RainDance," said Mr. Banerjee. "I look forward to
sharing with investors RainDance's product evolution and novel
applications in large, fast growing and high value markets. We have a
strong track-record of success and are preparing to launch our
innovative digital PCR product that sets the new gold standard in PCR
sensitivity and multiplexing capabilities."
For more information please visit RainDance online at: www.RainDanceTech.com.
About RainDance Technologies
RainDance Technologies, the Digital Biology? Company, is pioneering the
use of high-throughput picodroplet-based analysis in human health and
life science research. The company's core RainStorm? technology
generates millions of discrete droplets that can encapsulate a single
molecule, cell or reaction and be digitally analyzed and sorted one at a
time. The power, precision and simplicity of picodroplets enable
researchers to answer complex questions with unprecedented sensitivity
and quantitation. The complete RainDance solution includes automated
instrumentation, customizable bioinformatics and high-value consumables
and reagents for applications including targeted next-generation DNA
sequencing, methylation, digital PCR and single cell analysis. Based in
Lexington, Massachusetts, the company supports scientists around the
world through its international sales and support operations and a
global network of distributors and service providers. For more
information, please visit www.RainDanceTech.com.
For research use only. Not for use in diagnostics procedures.
RainDance Technologies, the RainDance Technologies logo, Digital
Biology, DeepSeq, ONCOSeq, and MethylSeq are trademarks of RainDance
Technologies, Inc. All other brands may be trademarks of their
respective holders.
